Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28367514 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL9144151 | 0.80 | TLR8 (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL6118671 | 0.80 | FBP1 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL17561705 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL13543521 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL9753219 | 0.80 | TLR8 (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL3194071 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL3295739 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2541919 | 0.80 | TLR8 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL14957163 | 0.79 | TLR8 (0.42) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054664-A1 | METABOLIC SUPPLEMENT FORMULATION AND METHODS OF USE FOR TREATING DEPRESSION AND ANXIETY | HAWKINS GERMAINE BERNARD (US) | 2020-02-20 | — | — | US | claimed |
| EP-2445518-A1 | COBALAMIN TAXANE BIOCONJUGATES FOR TREATING EYE DISEASE | Osiris Therapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-20110166097-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | OSIRIS THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2320728-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | Osiris Therapeutics, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010088287-A1 | COBALAMIN TAXANE BIOCONJUGATES FOR TREATING EYE DISEASE | GEBHARD JOHN R (US) | 2010-08-05 | — | — | WO | claimed |
| JP-2010509488-A | — | — | 2010-03-25 | — | — | JP | claimed |
| WO-2010011662-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | INFLABLOC PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100016256-A1 | Taxane Compounds for Treating Eye Disease | OSIRIS THERAPEUTICS, INC | 2010-01-21 | — | — | US | claimed |
| EP-2139469-A2 | COBALAMIN TAXANE BIOCONJUGATES | Inflabloc Pharmaceuticals, Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| EP-0700295-A4 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1998-09-30 | — | — | EP | claimed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| US-5548064-A | COLONY STIMULATING FACTOR; ORAL ADMINISTERING | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1996-08-20 | — | — | US | claimed |
| CN-1126436-A | Vitamin B12 mediated oral delivery systems for GCSF and EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| EP-0700295-A1 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-13 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027613-A1 | VITAMIN B12 MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016256-A1 | Taxane Compounds for Treating Eye Disease | TTR, BTD, MTHFD1 | CYP1A2 1237/4885CYP3A4 3978/4885CYP2C9 2914/4885 |
| US-20110166097-A1 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE | TTR, BTD, MTHFD1 | CYP1A2 1237/4885CYP3A4 3978/4885CYP2C9 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.